Cargando…
Does prior exposure to immune checkpoint inhibitors treatment affect incidence and mortality of COVID-19 among the cancer patients: The systematic review and meta-analysis
BACKGROUND: Immune checkpoint inhibitors (ICIs) treatment among cancer patients has been shown to have antiviral effects by reactivating exhausted T cells. However, they could also trigger inflammatory storm. Therefore, prior exposure to ICIs may influence the risk of SARS-CoV2 infection and subsequ...
Autores principales: | Liu, Yang, Liu, Shuo, Qin, Yujun, Zhao, Lei, Li, Yiliang, Zhou, Chenghui, Chen, Wei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Authors. Published by Elsevier B.V.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8502698/ https://www.ncbi.nlm.nih.gov/pubmed/34688136 http://dx.doi.org/10.1016/j.intimp.2021.108242 |
Ejemplares similares
-
Immune Checkpoint Inhibitors—Associated Cardiotoxicity
por: Li, Chenghui, et al.
Publicado: (2022) -
Immune Checkpoint Inhibitor Rechallenge After Prior Immune Toxicity
por: Bylsma, Sophia, et al.
Publicado: (2022) -
Safety of sequential immune checkpoint inhibitors after prior immune therapy
por: Awidi, Muhammad, et al.
Publicado: (2022) -
Clinical outcomes of coronavirus disease 2019 (COVID‐19) in cancer patients with prior exposure to immune checkpoint inhibitors
por: Wu, Qiuji, et al.
Publicado: (2020) -
Characteristics of Tumor-Infiltrating Lymphocytes Prior to and During Immune Checkpoint Inhibitor Therapy
por: Plesca, Ioana, et al.
Publicado: (2020)